Remibrutinib (Rhapsido) is now the first FDA-approved treatment for symptomatic dermographism.
RemIND: 29.3% complete hive response vs 14.0% with placebo at week 12.
Clinician FAQ ↓
hubs.li/Q04DmYPk0

🔔👥 CONFERENCE COVERAGE: Today, Dermatology Times is on-site in Philadelphia with Joel Gelfand, MD, MSCE, for DPEC: Dermatology in Pharma Educational Collaborative!

#DPEC2026 #DermatologyTimes #Dermatology #DermatologyResearch

📖 BETWEEN THE LINES: Remibrutinib is reshaping the treatment landscape for chronic inducible urticaria (CIndU).

Read more: hubs.li/Q04Dv1B30

#BetweenTheLines #Remibrutinib #ChronicInducibleUrticaria #Dermatology

✍⏳ THE PRACTICE BRIEF: New treatment options are expanding dermatologic care, but access barriers and evolving clinical guidance continue to shape everyday practice.

🔗 Read more: hubs.li/Q04Dv2RG0

#ThePracticeBrief #NPPAConnect #AdvancedPractice #Dermatology

💡 NPPA CONNECT: Nurse practitioners are making an impact far beyond the exam room. In recognition of National Nurse Practitioner Week, explore the growing influence of NPs across the profession.

hubs.li/Q04Dv0PR0

#NPWeek #NursePractitioners #NPPAConnect #AdvancedPractice

Remibrutinib (Rhapsido) is now the first FDA-approved treatment for symptomatic dermographism.

RemIND: 29.3% complete hive response vs 14.0% with placebo at week 12.
Clinician FAQ ↓
hubs.li/Q04DmYSL0

🚨 NEW TODAY: The American Academy of Dermatology Association (AADA) is warning of a potential 6% Medicare payment cut for dermatologists in 2027.

Read more: hubs.li/Q04DsW-q0

#Medicare #Dermatology #HealthCarePolicy #PhysicianReimbursement

Lisa Swanson, MD, joins host Andrew Krakowski, MD, to discuss the often-overlooked impact of psoriasis on children’s quality of life in this episode of Don’t Be Rash, supported by Arcutis.

Watch the full episode here:

#PediatricPsoriasis #DontBeRash

#Sponsored by Sun Pharmaceutical Industries, Inc.

Treatment decisions for locally advanced basal cell carcinoma often extend beyond tumor removal alone. Cosmetic concerns, surgical fatigue, and recovery burden may all influence patient care. hubs.li/Q04ydPz_0

Remibrutinib (Rhapsido) is now the first FDA-approved treatment for symptomatic dermographism.
RemIND: 29.3% complete hive response vs 14.0% with placebo at week 12.
Check out our clinician FAQ ↓
Swipe through →
hubs.li/Q04D5p-50
#Dermatology #Urticaria

⭐️ CASE-BASED INSIGHTS: Not all hedgehog inhibitors are interchangeable when treating locally advanced basal cell carcinoma.

hubs.li/Q04Db6nS0

#BasalCellCarcinoma #BCC #SkinCancer #Dermatology

💡 EXPERT INSIGHTS: Women's health considerations play an important role in managing psoriasis and atopic dermatitis.

Read more: hubs.li/Q04Db2nB0

#WomensHealth #Psoriasis #AtopicDermatitis #Dermatology

Remibrutinib (Rhapsido) is now the first FDA-approved treatment for symptomatic dermographism.

RemIND: 29.3% complete hive response vs 14.0% with placebo at week 12.
Clinician FAQ ↓
hubs.li/Q04D5mYB0

#Dermatology #Urticaria

🗓🌟 TOP 5 OF THE MONTH: Which Dermatology Times stories caught readers’ attention in October?

See the top 5: hubs.ly/Q04D1lZ-0

#Top5 #DermatologyTimes #Dermatology #MonthInReview

🗓 MONTH IN REVIEW: October brought major FDA approvals, new clinical data, pipeline updates, and expert insights across dermatology.

hubs.li/Q04D1l5F0

#MonthInReview #Dermatology #DermatologyNews #DermatologyResearch

Borderline resectable cSCC: operate first, or start with neoadjuvant immunotherapy? David Carr, MD, MPH, says this is the kind of case where neoadjuvant immunotherapy belongs in the conversation.

Watch the full series: hubs.li/Q04CH78x0

#Dermatology #SkinCancer #cSCC

📚 STUDY FINDINGS: Dupilumab treatment was associated with catch-up growth in children with severe atopic dermatitis, highlighting the potential impact of effective disease control beyond the skin.

Read more: hubs.li/Q04CVTQt0

#Dupilumab #AtopicDermatitis

💡 WHAT TO KNOW: Tildrakizumab’s newly expanded indication brings another treatment option to adults with active psoriatic arthritis.

Read more: hubs.li/Q04CWvxZ0

#Tildrakizumab #PsoriaticArthritis #Psoriasis #Dermatology

❗ ICYMI: Key takeaways from today's FDA approval of tildrakizumab for adults with active psoriatic arthritis: it is a high-affinity IL-23p19 inhibitor already established in plaque psoriasis.

Read more: hubs.li/Q04CWmtN0

👥 CONFERENCE HIGHLIGHTS: Practical pearls from Elevate-Derm Summer span hair loss, hyperpigmentation, care of older adults, and JAK inhibitor management.

Read more: hubs.li/Q04CQRr90

#ElevateDerm #NPPAConnect #AdvancedPractice #Dermatology